Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA)

Haidar et al., NCT05648110, SUPERNOVA, NCT05648110, Jun 2026
ProphylaxisDouble-blind RCT · NCT05648110 · 57 patients · multinational
AZD5156 for COVID-19
SUPERNOVA Haidar et al. NCT05648110 · June 2026
Outcome
Improvement
Relative Risk · 95% CI
Mortality
-139%2.39 · 0.10 to >9
00.511.52+
← AZD5156
reduces riskAZD5156
increases risk →
Trial underpowered to detect differences
RCT 57 patients showing no significant differences with AZD5156 (sipavibart + cilgavimab).
Important missing comments or errors? Let us know.
Study covers AZD5156 and tixagevimab/cilgavimab.
risk of death, 139.0% higher, RR 2.39, p = 1.00, treatment 1 of 41 (2.4%), control 0 of 16 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), all-cause mortality, day 451, registry.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Haidar et al., 18 Jun 2026, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, preprint, 1 author, trial NCT05648110 (history) (SUPERNOVA). Contact: taylor.cohen@astrazeneca.com.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0